https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49803 38 years (1.34; 1.04–1.73); those with disease duration > 7 years (1.33; 1.01–1.74); those with EDSS score < 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.]]> Wed 31 May 2023 15:59:42 AEST ]]> Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51652 Wed 13 Sep 2023 10:00:03 AEST ]]> The risk of secondary progressive multiple sclerosis is geographically determined but modifiable https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54611 Wed 06 Mar 2024 10:38:32 AEDT ]]> The effectiveness of natalizumab vs fingolimod - A comparison of international registry studies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38113 Wed 04 Aug 2021 11:40:28 AEST ]]> Multiple Sclerosis Relapses Following Cessation of Fingolimod https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53300 Tue 21 Nov 2023 12:02:22 AEDT ]]> Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49895 Tue 13 Jun 2023 15:49:48 AEST ]]> Comparative effectiveness in multiple sclerosis: A methodological comparison https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53990 Thu 25 Jan 2024 13:04:15 AEDT ]]> Confirmed disability progression as a marker of permanent disability in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51965 Mon 25 Sep 2023 08:53:21 AEST ]]> Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> Disability accrual in primary and secondary progressive multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>